Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
13.90
+0.19 (1.39%)
At close: Aug 13, 2025, 4:00 PM
13.96
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:39 AM EDT
Keros Therapeutics Employees
Keros Therapeutics had 169 employees as of December 31, 2024. The number of employees increased by 33 or 24.26% compared to the previous year.
Employees
169
Change (1Y)
33
Growth (1Y)
24.26%
Revenue / Employee
$1,377,775
Profits / Employee
$111,083
Market Cap
564.55M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KROS News
- 7 days ago - Keros to Exclusively Prioritize the Clinical Advancement of KER-065 - GlobeNewsWire
- 7 days ago - Keros Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - GlobeNewsWire
- 2 months ago - ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal - PRNewsWire
- 2 months ago - Keros Announces Return of $375 Million in Excess Capital to Stockholders - GlobeNewsWire
- 2 months ago - Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - GlobeNewsWire
- 2 months ago - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees - GlobeNewsWire